Sensus Healthcare (NASDAQ:SRTS) Stock Rating Lowered by Wall Street Zen

Sensus Healthcare (NASDAQ:SRTS) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

Several other research analysts have also weighed in on SRTS. Zacks Research upgraded Sensus Healthcare from a “strong sell” rating to a “hold” rating in a report on Wednesday, October 22nd. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Sensus Healthcare in a research report on Thursday, January 22nd. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $8.00.

Sensus Healthcare Stock Performance

Shares of NASDAQ SRTS opened at $3.86 on Friday. Sensus Healthcare has a 52-week low of $3.03 and a 52-week high of $5.92. The stock has a market cap of $63.38 million, a P/E ratio of -8.21 and a beta of 1.21. The firm has a 50 day moving average price of $4.46 and a 200 day moving average price of $3.93.

Sensus Healthcare (NASDAQ:SRTS) last announced its quarterly earnings results on Thursday, February 12th. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.10). Sensus Healthcare had a negative return on equity of 14.82% and a negative net margin of 28.09%.The firm had revenue of $4.94 million for the quarter, compared to the consensus estimate of $8.35 million. Analysts predict that Sensus Healthcare will post 0.32 earnings per share for the current fiscal year.

Insider Activity at Sensus Healthcare

In other Sensus Healthcare news, Director Eric Sachetta acquired 7,000 shares of the business’s stock in a transaction dated Friday, November 21st. The shares were acquired at an average price of $3.93 per share, with a total value of $27,510.00. Following the completion of the transaction, the director directly owned 140,113 shares in the company, valued at $550,644.09. This trade represents a 5.26% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Joseph C. Sardano bought 25,000 shares of Sensus Healthcare stock in a transaction that occurred on Tuesday, November 18th. The shares were acquired at an average price of $4.03 per share, with a total value of $100,750.00. Following the acquisition, the chief executive officer directly owned 1,200,293 shares of the company’s stock, valued at $4,837,180.79. The trade was a 2.13% increase in their position. The SEC filing for this purchase provides additional information. Insiders have bought a total of 33,000 shares of company stock valued at $132,060 over the last ninety days. Company insiders own 8.90% of the company’s stock.

Hedge Funds Weigh In On Sensus Healthcare

A number of large investors have recently modified their holdings of SRTS. State Street Corp increased its position in shares of Sensus Healthcare by 5.2% in the fourth quarter. State Street Corp now owns 69,252 shares of the company’s stock valued at $276,000 after acquiring an additional 3,400 shares during the last quarter. Geode Capital Management LLC grew its stake in Sensus Healthcare by 2.5% in the second quarter. Geode Capital Management LLC now owns 153,917 shares of the company’s stock valued at $730,000 after purchasing an additional 3,766 shares in the last quarter. Sachetta LLC grew its stake in Sensus Healthcare by 6.8% in the fourth quarter. Sachetta LLC now owns 148,508 shares of the company’s stock valued at $591,000 after purchasing an additional 9,500 shares in the last quarter. Vise Technologies Inc. acquired a new position in shares of Sensus Healthcare during the 2nd quarter worth approximately $52,000. Finally, Mindset Wealth Management LLC raised its stake in shares of Sensus Healthcare by 28.1% during the 3rd quarter. Mindset Wealth Management LLC now owns 50,100 shares of the company’s stock worth $157,000 after purchasing an additional 11,000 shares in the last quarter. 25.30% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Sensus Healthcare

Here are the key news stories impacting Sensus Healthcare this week:

• Positive Sentiment: Publication of dedicated CPT codes for superficial radiation therapy (SRT) to treat non‑melanoma skin cancer — a potential boost to reimbursement and broader adoption that could improve unit economics over time. Business Wire: Q4 2025 Results & CPT Codes
• Positive Sentiment: Management is explicitly targeting profitability in 2026 by expanding reimbursement, diversifying the customer base and driving adoption — a constructive strategic path if execution and reimbursement traction continue. Seeking Alpha: Profitability Target 2026
• Neutral Sentiment: Earnings call transcripts and highlights show management discussing reimbursement progress and operating initiatives; no material upside guidance was issued to offset the quarter’s miss. Useful for detail but did not reverse market reaction. MSN: Q4 2025 Earnings Call Transcript
• Negative Sentiment: Q4 results materially missed expectations: EPS of ($0.19) vs. consensus (~($0.09)) and revenue $4.94M vs. ~$8.35M consensus; the company reported a quarterly net loss and negative margins — a near‑term catalyst for selling pressure. Company Press Release: Q4 2025 Results
• Negative Sentiment: Longer‑term shareholder returns have been weak (article notes a ~36% loss over three years), underscoring investor sensitivity to execution and growth consistency. Yahoo Finance: Shareholder Returns

Sensus Healthcare Company Profile

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.